Clinical trials: Targeted Molecular Therapy
Schizophrenia
Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.
This application seeks renewed support for MH59803, "Dopaminergic substrates of startle gating across species," to extend a clear path of "bench-to-bedside" progress towards a critical paradigm shift in therapeutic models for…
- Trial name
- NCT02634684
- Testing
- Dextroamphetamine
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Metformin, Prediabetes
Metformin and Molecular Aging in Prediabetes
The incidence and prevalence of type 2 diabetes mellitus (T2DM) are increasing globally. The global prevalence of diabetes has nearly doubled since 1980, rising from 4.7% to 8.5% in the adult population.
- Trial name
- NCT07302932
- Testing
- Metformin treatment, Analyzed by qPCR for T/S ratio.
- Where
- India
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Diabetes Foundation, India
Brain Neuroimaging Biomarkers in Huntington Disease
Dynamic Neuroimaging Biomarkers in Huntington's Disease
There is no curative treatment available today in Huntington disease (HD) despite the identification of the mutated gene 20 years ago.
- Trial name
- HDeNERGY (NCT02639871)
- Where
- France
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents
A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935
The purpose of this study is to determine the brain cholesterol 24S-hydroxylase (CH24H) enzyme occupancy of TAK-935 after single oral dose in healthy participants using the positron emission tomography (PET) ligand [18F]MNI-792…
- Trial name
- NCT02497235
- Testing
- TAK-935, [18F]MNI-792 (tracer)
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Takeda
Rare Diseases, Aniridia
Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
The cross-sectional observational clinical study related to rare eye diseases is a multi-center study in which the hypothesis is that neurokinin 1 receptor and/or substance P expression is increased in REDs associated with…
- Conditions
- Rare Diseases, Aniridia, Neurotrophic Keratopathy, Limbal Stem Cell Deficiency
- Trial name
- NCT06412718
- Volunteers
- 274 people, healthy volunteers welcome
- Sponsor
- IRCCS Ospedale San Raffaele